Delivery Order SPE2DB25D3012-SPE2DB25FWZKF
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Ocrevus 300 mg/10 mL vials, valued at $96,154.24 with a firm fixed price structure. The award is non-competitive with no set-aside designation and is scheduled for completion by October 2, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $48,077.16. The contract is firm fixed price with no set-aside designation, indicating competitive award, and is scheduled for completion by August 28, 2025. AmerisourceBergen will perform the work from its corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $48,077.16 firm fixed price delivery order to AmerisourceBergen Drug Corp for 10 milliliter vials of Ocrevus 300 mg on September 10, 2025, with an ultimate completion date of October 1, 2025. This contract was not set-aside and represents a competitive award to the pharmaceutical distributor. Performance will occur at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child delivery order, this award falls under AmerisourceBergen's...
- AmerisourceBergen Drug Corp was awarded a delivery order on August 4, 2025, by the Defense Logistics Agency Medical Supply Chain for the supply of Ocrevus 300 mg/10 mL vials. The contract is valued at $120,192.80 under a firm fixed-price arrangement with an ultimate completion date of August 25, 2025. This non-competitive delivery order was issued as a child contract against a larger vehicle, leveraging AmerisourceBergen's established relationship with federal medical procurement. The place of...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 ml vials with a ceiling value of $72,115.74. The contract, which was competitively awarded with no set-aside designation, carries a firm fixed price structure and is scheduled for completion by August 21, 2025. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order operates under...
- The Defense Logistics Agency awarded a $120,192.80 delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ocrevus 300 mg/10 ml vials. This is a firm fixed price, non-set-aside contract with a completion date of September 10, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a delivery order valued at $12,019.28 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, scheduled for completion by September 22, 2025. The pharmaceutical will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a child contract issued under...
- The Defense Logistics Agency awarded a delivery order valued at $72,115.74 to AmerisourceBergen Drug Corp for the supply of Ocrevus (300 mg/10 mL vial) pharmaceutical product. This is a firm fixed price, non-set-aside contract with an ultimate completion date of October 2, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran...
- The Defense Logistics Agency awarded a $120,192.80 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This is a firm fixed-price contract with an ultimate completion date of August 14, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation, reflecting the contractor's demonstrated capability to meet federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $36,057.84 to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This firm fixed-price, non-set-aside contract is scheduled for completion by August 8, 2025, with performance at the contractor's location in Conshohocken, Pennsylvania. AmerisourceBergen, a major pharmaceutical distributor and critical vendor for federal medical procurement, will fulfill this order as part of its ongoing...
- SPE2DB25D3012Indefinite Delivery Contract
- SPE2DB25D3012-SPE2DB25FWZKFDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $72,115.74 to AmerisourceBergen Drug Corp for the supply of Ocrevus 300 mg/10 mL vials on August 20, 2025, with an ultimate completion date of September 11, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The prime vendor contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Ocrevus is a specialty pharmaceutical used in the treatment of multiple sclerosis, reflecting the critical nature of the medical commodities supplied under this arrangement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. The company demonstrates significant capability in fulfilling federal requirements through its extensive portfolio of delivery orders covering multiple therapeutic domains, from specialty medications to vaccines and medical devices. This award supports the Defense Health Agency and other government healthcare systems through the flexible and comprehensive contract vehicle that enables efficient procurement of essential pharmaceutical products.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $72.1k | 8/20/25 |